Supp-Figure 1



Supplementary figure 1. (a-b) Western blotting determined the level of H3K4 di-me (me2), H3K4 tri-me (me3) in the cells treated with MM-102 for various times as indicated. (c-d) Western blotting determined the level of H3K4 di-me (me2), H3K4 tri-me (me3) in the cells treated with JIB-04 for various time as indicated.

Supp-Figure 2



Supplementary figure 2. (a-b) Annexin-PI staining determined the apoptotic cells. Cells were treated with 1μg/ml cisplatin and 50μM MM-102 for 24h. (c-d) Western blotting determined the level of cleaved-PARP1 (c-PARP1) as indicated. Cells were treated with 1μg/ml cisplatin and 50μM MM-102 for 24h.

Supp-Figure 3



Supplementary figure 3. (a-c) Western blotting determined the expression of KDM5A, KDM5C, and KDM5D in each cell as indicated. (d) Western blotting determined the expression of XRCC1 and KDM5B as indicated. KDM5B knockdown BGC823/DDP Cells were treated with 5μg/ml cisplatin for 24h.

Supp--Figure 4



Supplementary figure 4. (a) RT-qPCR determined the expression of KDM5B mRNA in each cell as indicated. (b) Western blotting determined the expression of KDM5B in SGC7901 cells treated with 50μM MG132 for 6h. (c) immunoprecipitation determined the interaction of flag-KDM5B (flag-tag) and HSP90 in SGC7901 cells. (d) Western blotting determined the expression of HSP90 in each cell as indicated. (e-f) Western blotting determined the expression of KDM5B in BGC823/DDP cells treated with 17-AAG as indicated.